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Breakthrough discoveries identifying common genetic causes for amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD) have transformed our view of these disorders. They share unexpectedly
similar signatures, including dysregulation in common molecular players including TDP-43, FUS/TLS,
ubiquilin-2, VCP, and expanded hexanucleotide repeats within the C9ORF72 gene. Dysfunction in RNA pro-
cessing and protein homeostasis is an emerging theme. We present the case here that these two processes
are intimately linked, with disease-initiated perturbation of either leading to further deviation of both protein
and RNA homeostasis through a feedforward loop including cell-to-cell prion-like spread that may represent
the mechanism for relentless disease progression.Introduction
Amyotrophic lateral sclerosis (ALS, familiarly known in the United
States as Lou Gehrig’s disease) was first reported 140 years ago
by the great French physician Jean-Martin Charcot. The name
describes the key features of the disease: muscle wasting
(amyotrophic) due to the degeneration of lower motor neurons
and their axons and loss of upper motor neurons and their corti-
cospinal axonal tracts (lateral sclerosis). In contrast to ALS, fron-
totemporal dementia (FTD) (also known as frontotemporal lobar
degeneration [FTLD]) is a progressive neuronal atrophy with loss
in the frontal and temporal cortices and is characterized by per-
sonality and behavioral changes, as well as gradual impairment
of language skills. It is the second most common dementia after
Alzheimer’s disease (Van Langenhove et al., 2012).
Here, we review the key findings that have revealed a tangled
web in which multiple pathways are involved in disease initiation
and progression in ALS and FTD. RNA and protein homeostasis
pathways are intimately linked and their dysfunction is funda-
mentally involved in disease pathogenesis. Perturbation of either
pathway can amplify an initial abnormality through a feedforward
loop, which may underlie relentless disease progression.
Convergence of Pathogenic Mechanisms of ALS
and FTD
Largely indistinguishable, familial (10%) and sporadic (90%) ALS
are characterized by premature degeneration of upper and lower
motor neurons. Mutations in four genes (C9ORF72, SOD1,
TARDBP, and FUS/TLS) account for over 50% of the familial
cases (Table S1 available online). For FTD, a stronger genetic
contribution is reflected by the higher percentage (up to 50%)
of patients with a familial history. This includes the first two
identified causal genes encoding the microtubule-associated
protein tau (MAPT) (Hutton et al., 1998) and progranulin
(PGRN) (Baker et al., 2006; Cruts et al., 2006), which together ac-416 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.count for 10%–20% of FTD (Van Langenhove et al., 2012). More
rarely, mutations in TDP-43 and FUS/TLS are causal for FTD (re-
viewed in Lagier-Tourenne et al., 2010; Mackenzie et al., 2010a).
Recently, hexanucleotide expansion in the C9ORF72 gene
was found to be a common genetic cause for ALS and FTD
(DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012; Renton
et al., 2011) (Table S1).
It is estimated that 15% of FTD patients meet ALS criteria
(Ringholz et al., 2005), and ALS can be accompanied by cogni-
tive and behavioral impairment, with perhaps as much as 15%
of affected individuals also developing symptoms consistent
with a typical definition of FTD (Ringholz et al., 2005; Wheaton
et al., 2007). ALS and FTD are linked clinically, pathologically,
and mechanistically, and the diseases are now properly recog-
nized as representatives of a continuum of a broad neurode-
generative disorder, with each presenting in a spectrum of
overlapping clinical symptoms (Figure 1).
A breakthrough linking disease mechanisms for ALS and FTD
camewith the identification of TDP-43 as themajor ubiquitinated
protein found in both sporadic ALS patients and the most
frequent pathological form of FTD (Arai et al., 2006; Neumann
et al., 2006). This finding was followed by the discovery of muta-
tions in the gene encoding the RNA-binding protein TDP-43 in
5% of familial ALS cases (Kabashi et al., 2008; Sreedharan
et al., 2008; Van Deerlin et al., 2008) and rare patients with FTD
(Borroni et al., 2009; Kovacs et al., 2009).
Recognition that errors in RNA-binding proteins are causative
of ALS and FTD was quickly expanded, with mutations in
the fused in sarcoma/translocated in liposarcoma (FUS/TLS)
gene shown to account for an additional 5% of familial ALS
and also rare cases of FTD (Kwiatkowski et al., 2009; Vance
et al., 2009). Subsequent confirmation that FUS/TLS was pre-
sent in the pathological inclusions in most of the FTD patients
without TDP-43-containing inclusions has led to a proposed
AB
Figure 1. Clinical, Genetic, and Pathological Overlap of ALS and FTD
(A) ALS and FTD represent a continuum of a broad neurodegenerative disorder
with each presenting as extremes of a spectrum of overlapping clinical
symptoms (ALS in red and FTD in purple). Major known genetic causes for ALS
and FTD are plotted according to the ratio of known mutations that give rise to
ALS or FTD.
(B) Pathological protein inclusions in ALS and FTD, according to the major
protein misaccumulated. Inclusions of TDP-43 and FUS/TLS in ALS and FTD
reflect the pathological overlap of ALS and FTD.
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accumulated (Mackenzie et al., 2010b; Sieben et al., 2012).
These include FTLD-tau (45%), FTLD-TDP (45%), FTLD-FUS
(9%), and a remaining 1% named FTLD-UPS (for ubiquitin-pro-
teasome system) (Figure 1). Altogether, these findings highlight
two main discoveries: (1) TDP-43 and FUS/TLS, both RNA-bind-
ing proteins linked to multiple steps of RNA metabolism, are the
major protein components of pathological inclusions observed in
over 90% of ALS and over 50% of FTD patients, and (2) errors in
RNA processing may be central to ALS and FTD pathogenesis.
A further direct molecular link between ALS and FTDwas iden-
tification of a large intronic hexanucleotide expansion (400–
1,600 GGGGCC repeats) in the previously uncharacterized
gene C9ORF72 (named for its location on chromosome 9,
open reading frame 72) in families with either ALS, FTD, or
both (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012;
Renton et al., 2011). The expanded repeat in C9ORF72 is remi-
niscent of previously studied repeat expansion diseases (La
Spada and Taylor, 2010), especially myotonic dystrophy and
fragile X mental retardation syndrome, whose precedents sup-
port at least two possible pathogenic mechanisms: RNA-medi-
ated toxicity or haploinsufficiency.
ALS-, ALS/dementia-, and/or FTD-causing mutations were
also identified in genes involved in protein clearance pathways
or maintaining proper protein homeostasis, including ubiquilin-2
(UBQLN2) (Deng et al., 2011), vasolin-containing protein (VCP)
(Johnson et al., 2010; Watts et al., 2007), vesicle-associated
membrane protein-associated protein B (VAPB) (Nishimura
et al., 2004), p62/sequestosome (SQSTM1) (Fecto et al., 2011;Rubino et al., 2012; Teyssou et al., 2013), optineurin (OPTN)
(Maruyama et al., 2010), and chargedmultivesicular body protein
2B or chromatin modifying protein 2B (CHMP2B) (Parkinson
et al., 2006; Skibinski et al., 2005). Coupledwith protein aggrega-
tion as a major pathological hallmark of both ALS and FTD, the
genetic discoveries indicate that disruption in protein homeosta-
sis (or proteostasis) is a key characteristic of both diseases.
ALS- and FTD-Linked Genes Disrupt RNA Homeostasis
Identification of disease-linked mutations in TDP-43 and FUS/
TLS marked the beginning of a paradigm shift, highlighting dys-
functions in RNA metabolism as a central pathogenic pathway
in ALS and FTD. TDP-43 and FUS/TLS share similar structural
and functional properties with probable involvement in multiple
RNA processing steps (Lagier-Tourenne et al., 2010). ALS-
linked mutations have been identified in genes encoding
TAF15 (TATA-binding protein-associated factor 15) (Couthouis
et al., 2011; Ticozzi et al., 2011) and EWSR1 (Ewing’s sarcoma
breakpoint region 1) (Couthouis et al., 2012), two proteins that
are functionally and structurally similar to FUS/TLS, albeit the
mutations have not been proven to be causative of disease.
Altogether, with additional ALS-linked mutations in the RNA-
binding proteins angiogenin (Greenway et al., 2006), senataxin
(Chen et al., 2004), and ataxin-2 (Elden et al., 2010), disruption
in RNA homeostasis seems highly likely to play a central role
in ALS pathogenesis.
TDP-43 and FUS/TLS Reshape ALS and FTD
TDP-43 Mutation and Pathology in ALS and FTD
TDP-43 is a 414 amino acid protein containing two RNA recogni-
tion motifs (RRMs) followed by a glycine-rich, low-sequence
complexity prion-like domain (Kato et al., 2012; King et al.,
2012). TDP-43 can shuttle between the cytosol and the nucleus
(Ayala et al., 2008; Winton et al., 2008), although the majority of
TDP-43 appears to be nuclear in most cells at steady state. Path-
ological inclusions of TDP-43 can be found in the nucleus and
cytosol of neurons and glia, with abnormal phosphorylation and
ubiquitination of TDP-43 and the presence of truncated C-termi-
nal fragments (Arai et al., 2006; Neumann et al., 2006). More than
40mutations in sporadic and familial ALS, aswell as in rare cases
of FTD (reviewed in Lagier-Tourenne et al., 2010; Lattante et al.,
2013), are found clustered within the prion-like domain (so
named because of its similarity to fungal prions) (Figure S1).
In the absence of mutation, TDP-43 pathology can be found
in the majority of ALS patients, with the exception of patients
with SOD1 mutations (Mackenzie et al., 2007; Tan et al., 2007),
and is apparently indistinguishable between patients with or
without TDP-43 mutations (Pamphlett et al., 2009). Cells with
TDP-43 aggregates typically have concomitant loss of nuclear
TDP-43, indicating loss of nuclear TDP-43 function, while the
presence of cytoplasmic protein inclusions suggests gain of
one or more toxic properties. Thus, the pathogenic mechanisms
for TDP-43 are likely to be a combination of both loss-of-function
and gain-of-toxic properties.
Normal Function of TDP-43
TDP-43 was first identified as a protein that bound to the trans-
activation response (TAR) element of HIV human immunodefi-
ciency virus and was named TAR DNA-binding protein-43 kDa.Neuron 79, August 7, 2013 ª2013 Elsevier Inc. 417
Figure 2. Physiological Roles of TDP-43 and FUS/TLS in RNA Processing
Proposed roles for FUS/TLS include (1) association with TBP within the TFIID complex as a participant in the general transcriptional machinery and (2) binding to
long introns in a sawtooth-like pattern, consistent with cotranscriptional deposition. Both TDP-43 and FUS/TLS (3) associate with promoter regions. TDP-43
binds single-stranded TG-rich elements in promoter regions, thereby blocking transcription of the downstream gene. In response to DNA damage, FUS/TLS is
recruited in the promoter region of cyclin D1 (CCND1) by sense and antisense noncoding RNAs (ncRNAs) and represses CCND1 transcription. BothTDP-43 and
FUS/TLS (4) bind long intron-containing RNAs, thereby sustaining their levels. (5) TDP-43 and FUS/TLS control the splicing of >950 or >370 RNAs, respectively,
either via direct binding or indirectly. TDP-43 and FUS/TLS (6) bind long noncoding RNAs, (7) complex with Drosha (consistent with an involvement in miRNA
processing), and (8) bind 30UTRs of a large number of mRNAs. Both TDP-43 and FUS/TLS shuttle between the nucleus and the cytosol and are incorporated into
(9) transporting RNA granules and (10) stress granules, in which they form complexes with mRNAs and other RNA-binding proteins.
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with proteins involved in transcription (Ling et al., 2010; Sephton
et al., 2011), including methyl CpG-binding protein 2 (MeCP2)
(Sephton et al., 2011), whose mutations are causative for Rett
syndrome. Genome-wide approaches are now needed to iden-
tify the complete set of genes for which TDP-43 plays a tran-
scriptional role through its direct DNA binding. TDP-43 is
involved in many aspects of RNA-related metabolism, including
splicing, microRNA (miRNA) biogenesis, RNA transport and
translation, and stress granule formation by interacting with
numerous hnRNPs, splicing factors, and microprocessor pro-
teins (reviewed in Buratti and Baralle, 2012; Lagier-Tourenne
et al., 2010; Polymenidou et al., 2012) (Figure 2A).
TDP-43’s RNA Targets
An unbiased genome-wide approach was used to identify the
in vivo RNA targets for TDP-43 in mouse (Polymenidou et al.,418 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.2011) and human (Tollervey et al., 2011) brain. More conven-
tional methodology has also been used in an effort to identify
RNA targets of TDP-43 in rat cortical neurons (Sephton et al.,
2011), a mouse NSC-34 cell line (Colombrita et al., 2012), and
a human neuroblastoma cell line (Xiao et al., 2011). It is clear
that TDP-43 binds to more than 6,000 RNA targets in the brain,
roughly 30% of the total transcriptome (Figure 3). The localiza-
tion of TDP-43’s binding sites across different pre-mRNAs re-
veals its various roles in RNAmaturation. Indeed, intronic binding
of TDP-43 on long-intron (>100 kb)-containing RNA targets was
shown to be required for sustaining their normal levels (Polyme-
nidou et al., 2011). Splice site selection may be influenced by
TDP-43 binding near exon-intron junctions as well as in the in-
tronic regions far away (>2 kb) from the nearest exon (Polymeni-
dou et al., 2011; Tollervey et al., 2011). In addition, TDP-43 bind-
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Figure 3. Comparison of TDP-43 and FUS/
TLS RNA-Binding Properties
Data are taken from Polymenidou et al. (2011),
Lagier-Tourenne et al. (2012), Tollervey et al.
(2011), Sephton et al. (2011), Colombrita et al.
(2012), Rogelj et al. (2012), Hoell et al. (2011),
Ishigaki et al. (2012), and Nakaya et al. (2013).
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influence their regulatory roles.
TDP-43 levels matter greatly for normal RNA maturation.
Antisense oligonucleotide-mediated reduction of TDP-43 within
an otherwise normal mouse nervous system affects the
levels of more than 600 mRNAs and the splicing pattern of
another 950 (Polymenidou et al., 2011). TDP-43 also binds
to the 30UTRs of more than 1,000 transcripts (Polymenidou
et al., 2011; Tollervey et al., 2011), including its own mRNA,
presumably affecting nuclear or cytoplasmic RNA stability. It
also has binding sites on many ncRNAs whose functions are
not yet clearly defined but include chromatin remodeling,
transcription regulation, and posttranscriptional processing.
Among these, TDP-43 binds to long (>200 base) ncRNAs,
including nuclear-enriched autosomal transcript 1 (NEAT1)
and metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) (Tollervey et al., 2011). Expression of both NEAT1
and MALAT1 is elevated in FTD-TDP (also known as FTLD-
TDP) patients, which correlates with increased TDP-43 associ-
ation with both ncRNAs (Tollervey et al., 2011). These data
suggest that TDP-43 may affect RNA metabolism, including
>300 mRNAs without TDP-43 binding sites but whose abun-
dance increases through an indirect mechanism when TDP-
43 is reduced (Polymenidou et al., 2011).
The binding of TDP-43 to small (<200 base) ncRNAs and
miRNAs remains largely unexplored. Nonetheless, the associa-
tion of TDP-43 with Drosha microprocessor (Ling et al., 2010)
and Dicer complexes (Freibaum et al., 2010; Kawahara and
Mieda-Sato, 2012) is suggestive of a TDP-43 involvement in
miRNA biogenesis. Indeed, let-7b miRNA is downregulated,
whereas miR-663 is upregulated after reduction in TDP-43
(Buratti et al., 2010).
FUS/TLS Mutation and Pathology in ALS and FTD
ALS/FTD-linked mutations in FUS/TLS are clustered into two
groups: mutations in the low-complexity/prion-like domain and
mutations in the C-terminal nuclear localization signal (NLS)
(Figure S1). Mutations in the latter group typically lead toNeuron 7increased cytoplasmic localization of
FUS/TLS (Kwiatkowski et al., 2009;
Vance et al., 2009) and several are asso-
ciated with juvenile onset ALS (Ba¨umer
et al., 2010; Belzil et al., 2012; Huang
et al., 2010; Yamashita et al., 2012).
Distinct patterns of FUS pathology
have been correlated with disease
severity and mutation (Mackenzie et al.,
2011). Early-onset ALS cases are charac-
terized by basophilic inclusions and
round neuronal cytoplasmic FUS inclu-sions, whereas late-onset ALS cases are characterized by
tangle-like FUS-containing inclusions in both neurons and glial
cells. FUS inclusions in the absence of FUS mutations have
also been reported in FTD, Huntington’s disease, and spinocer-
ebellar ataxia 1 and 2 (reviewed in Lagier-Tourenne et al., 2010).
Normal Function of FUS/TLS
Similar to TDP-43, FUS/TLS can bind to single- and double-
stranded DNA, as well as RNA, and almost certainly participates
in a wide range of cellular processes (Lagier-Tourenne et al.,
2010; Tan and Manley, 2009).
Transcription. All three members of the FET (FUS/TLS,
EWSR1, and TAF-15) family have been shown to associate
with RNA polymerase II (RNAP II) and its general transcription
factor TFIID. FUS/TLS and TAF15 fractionate with different pop-
ulations of TFIID complexes, suggesting that they may affect
different promoters (Bertolotti et al., 1996). It is likely that FUS/
TLS can affect the transcription of specific genes through its
association with several nuclear hormone receptors (Powers
et al., 1998) and gene-specific transcription factors. Indeed, a
recent study identified potential FUS/TLS-response elements
of many target genes, indicative of transcriptional activation or
repression directly by FUS/TLS (Tan et al., 2012). FUS/TLS can
also associate with TBP and TFIIIB to repress transcription by
RNAP III, which transcribes small structural and catalytic RNAs
(Tan and Manley, 2010).
Splicing. FUS/TLS has been identified as part of the spliceo-
some machinery in three independent proteomic studies (Hart-
muth et al., 2002; Rappsilber et al., 2002; Zhou et al., 2002).
The association of FUS/TLS with the spliceosome and various
splicing factors initially implicated FUS/TLS in a cotranscriptional
role and/or splicing regulation of pre-mRNAs, a prediction vali-
dated by demonstration that about 1,000 RNAs change in
splicing pattern or abundance in a FUS/TLS-dependent manner
in the mouse brain (Lagier-Tourenne et al., 2012) (Figure 3).
FUS/TLS’s RNA Targets
Genome-wide approaches (summarized in Figure 3) have identi-
fied more than 8,000 in vivo RNA targets for FUS/TLS in mouse9, August 7, 2013 ª2013 Elsevier Inc. 419
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(Lagier-Tourenne et al., 2012), and more than 6,800 in various
cell lines (Colombrita et al., 2012; Hoell et al., 2011; Ishigaki
et al., 2012; Nakaya et al., 2013). A GUGGU sequence is the
most prominent binding motif (Lagier-Tourenne et al., 2012). In
addition, AU-rich stem loops bound by FUS/TLS have also
been proposed (Hoell et al., 2011). A sawtooth-like binding
pattern to long introns (Lagier-Tourenne et al., 2012; Rogelj
et al., 2012) is consistent with cotranscriptional deposition of
FUS/TLS and suggests that FUS/TLS remains bound to pre-
mRNAs until splicing is completed. In addition, FUS/TLS shows
enrichment in binding to 30UTRs and exons.
Interestingly, RNAs bound by TDP-43 and FUS/TLS are largely
distinct (Lagier-Tourenne et al., 2012; Rogelj et al., 2012).
Indeed, depletion of FUS/TLS from an otherwise normal adult
mouse nervous system alters levels or splicing of >970 mRNAs,
most of which are distinct from RNAs dependent on TDP-43.
Remarkably, only 45 RNAs are reduced upon depletion of either
TDP-43 or FUS/TLS from mouse brain, including mRNAs tran-
scribed from genes with exceptionally long introns and that
encode proteins essential for neuronal integrity (Lagier-Tourenne
et al., 2012). A subset of these is significantly lowered after TDP-
43 or FUS/TLS depletion in stem cell-derived human neurons
and in TDP-43 aggregate-containing motor neurons in sporadic
ALS, evidence pointing to a common loss-of-function pathway
as one component underlyingmotor neuron death frommisregu-
lation of TDP-43 or FUS/TLS (Lagier-Tourenne et al., 2012).
Cytoplasmic Functions of TDP-43 and FUS/TLS
TDP-43 and FUS/TLS in Cytoplasmic RNA Granules
TDP-43 and FUS/TLS shuttle from the nucleus to the cytosol
(Ayala et al., 2008; Zinszner et al., 1997), where they have been
associated with cytoplasmic RNA granules that contain non-
translating mRNAs. These granules include processing bodies
(P bodies), which contain RNA decay machinery (Buchan and
Parker, 2009), stress granules, which contain translationmachin-
ery (Anderson and Kedersha, 2009), and transporting RNP gran-
ules, which contain RNAs to be locally translated (Kiebler and
Bassell, 2006).
TDP-43 and FUS/TLS at the Synapse
Deletion of FUS/TLS has produced abnormal dendritic and spine
morphology in cultured hippocampal neurons (Fujii et al., 2005).
Evidence suggests that FUS/TLS may play an important role in
regulating synaptic function, possibly through local transport
and translation. In dendrites of cultured hippocampal neurons,
TDP-43 has been shown to colocalize with fragile X mental retar-
dation protein (FMRP) and staufen, two proteins that mark trans-
porting RNP granules and P bodies (Wang et al., 2008). Given the
evidence that TDP-43 and FUS/TLS bind to many RNA targets
important for synaptic function and that TDP-43 and FUS/TLS
localize to dendrites in response to neuronal activation (Fujii
et al., 2005; Wang et al., 2008), dysfunction of TDP-43 or FUS/
TLS is highly likely to alter synaptic function.
Assembly of RNA Granules through Prion-like Domains
Both TDP-43 and FUS/TLS contain low-sequence complexity
(LC), fungal prion-like domains (King et al., 2012), for which a
normal function in RNA granule assembly has recently been pro-
posed (Han et al., 2012b; Kato et al., 2012). Assembly of the LC420 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.domain of FUS/TLS produces amyloid-like fibers that, in contrast
to pathological amyloid inclusions, are reversible (Kato et al.,
2012). Induced assembly of LC domains—along with their linked
RNA-binding domains—provides a basis for RNA granule
assembly and possibly for cell-to-cell spreading.
Disease Mechanisms for Mutant TDP-43 and FUS/TLS
Evidence for Gain of Toxicity from Mutant TDP-43
Multiple transgenic approaches have been employed to identify
properties of mutant TDP-43. We focus here only on mammalian
models; readers are directed to excellent reviews elsewhere on
yeast, Drosophila, C. elegans, and other animal models (Da
Cruz and Cleveland, 2011; Joyce et al., 2011; McGoldrick
et al., 2013). It should be acknowledged that the multiple efforts
that have produced TDP-43 transgenic mice and rats have—for
the most part—been disappointing. One effort (with a prion-
promoted TDP-43Q331K) did produce age-dependent, mutant-
dependent motor neuron disease in which about half of the lower
motor neurons died, but disease then plateaued despite con-
tinued mutant TDP-43 accumulation at a constant level (Arnold
et al., 2013). Mutant TDP-43-dependent degeneration of lower
(but not upper) motor neurons occurred without loss of nuclear
TDP-43 or accumulation of TDP-43 aggregates but was accom-
panied by both loss and gain of splicing function of selected RNA
targets at an early disease stage. Thus, disease mechanism is
apparently both gain of aberrant property and loss of function.
Inexplicably, a similar prion-promoted transgenic line (TDP-
43A315T) develops disease with very different characteristics:
upper motor neuron loss (Wegorzewska et al., 2009) with very
modest lower motor neuron disease, prior to death from bowel
obstruction (Esmaeili et al., 2013; Guo et al., 2012).
Additional TDP-43 transgenic efforts have established that
increased TDP-43 levels (by less than a factor of 2) of either
wild-type or mutant TDP-43 are highly deleterious (Igaz et al.,
2011; Wils et al., 2010). This has revealed a crucial role for an
autoregulatory pathway that maintains TDP-43 RNA levels. Evi-
dence for autoregulation of TDP-43 has been repeatedly seen:
inactivation of one copy of TDP-43 in mice does not affect either
themRNA or protein level of TDP-43 (Kraemer et al., 2010; Seph-
ton et al., 2010). Autoregulation is mediated, at least in part, by
TDP-43-dependent splicing of an intron in the 30UTR of its own
mRNA (Avendan˜o-Va´zquez et al., 2012; Ayala et al., 2011b; Pol-
ymenidou et al., 2011). Splicing of this intron generates an unsta-
ble RNA degraded by nonsense-mediated decay (Polymenidou
et al., 2011). An additional proposal is that this TDP-43-depen-
dent 30UTR splicing event activates a cryptic polyadenylation
site whose use leads to nuclear retention of TDP-43 RNA
(Avendan˜o-Va´zquez et al., 2012).
Increasing TDP-43 levels in mice and rats (by expression of
RNAs missing the autoregulatory sequences (Wegorzewska
et al., 2009; Wils et al., 2010; Igaz et al., 2011; Arnold et al.,
2013) or by disrupting autoregulation (Igaz et al., 2011) has pro-
duced neurodegeneration. The level of expression determines
the severity of disease (e.g., Wils et al., 2010; Igaz et al., 2011;
Arnold et al., 2013). Mice expressing autoregulated wild-type
and ALS-linked mutant genomic TDP-43 transgenes develop
very mild, late-onset cognitive andmotor deficits but without pa-
ralysis (Swarup et al., 2011). Age-dependent, mutant-dependent
Neuron
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to a level similar to the normal level of endogenous TDP-43
(Arnold et al., 2013). Expression of genes missing the autoregu-
latory 30UTR—thereby permitting accumulation of mutant TDP-
43M337V (to an undetermined level)—drives paralysis in rats
within 35 days after inducing transgene expression broadly
(Zhou et al., 2010) or within 15 days when the transgene is
induced panneuronally (Huang et al., 2012).
TDP-43 Loss of Function in Disease
Loss of nuclear function of TDP-43 is clearly a component of the
disease process, as nuclear clearing accompanied by cyto-
plasmic accumulation of TDP-43 has been universally reported
in surviving neurons in patients with TDP-43 mutant-mediated
ALS (Van Deerlin et al., 2008). Not unexpectedly, TDP-43 is an
essential gene in mice, yielding embryonic lethality (Chiang
et al., 2010; Kraemer et al., 2010; Sephton et al., 2010; Wu
et al., 2010), while TDP-43 heterozygote mice are viable and
fertile with autoregulation maintaining nearly normal TDP-43
levels (Kraemer et al., 2010).
Ubiquitous postnatal removal of TDP-43 through conditional
TDP-43 gene inactivation produced rapid lethality without motor
neuron disease (Chiang et al., 2010). Selective removal of TDP-
43 from motor neurons produced age-dependent progressive
motor neuron degeneration with ALS-like pathology, although
in one study the mice lived a normal life span (Iguchi et al.,
2013) and in the other study only the male mice developed
pathology and phenotype (Wu et al., 2012). These observations
are consistent with the notion that while neuronal loss of function
of TDP-43 may contribute to disease development and progres-
sion, it is insufficient to produce fatal motor neuron disease.
TDP-43’s RNA Targets and Disease Pathogenesis
Among the more than 6,000 RNAs normally bound by TDP-43—
and the 1,500 who are changed in abundance or splicing pattern
when nuclear TDP-43 is depleted (Figure 3)—are TDP-43 itself,
FUS/TLS, glial excitatory amino acid transporter-2 (EAAT2),
amyloid beta precursor protein (APP), presenilin, huntingtin,
multiple ataxins, a-synuclein, progranulin, and tau (Polymenidou
et al., 2011; Sephton et al., 2011). The most prominently affected
class of RNAs are pre-mRNAs with exceptionally long introns
(>100 kb), whose expression is enriched in brain and whose en-
coded proteins are involved in synaptic activity and functions,
including parkin 2 (PARK2), neurexin 1 and 3 (NRXN1 and
NRXN3), and neuroligin 1 (NLGN1), whose mutations are associ-
ated with various neurological diseases.
Additionally, among the >600 RNAs whose splicing patterns
are altered when TDP-43 levels are reduced are FUS/TLS itself
and EAAT2, with expression of the latter also reduced in FTD-
TDP brain (Tollervey et al., 2011). Many ALS-linked genes,
including ALSIN, CHMP2B, FIG4, VAPB, and VCP, are bound
by TDP-43, and their expression is modestly altered upon
TDP-43 depletion (Polymenidou et al., 2011). TDP-43 also regu-
lates the splicing of sortilin, a tentative receptor for progranulin
(Hu et al., 2010), whose mutations are linked to FTD-TDP.
Misregulation of sortilin splicing by reduction in TDP-43 affects
progranulin metabolism (Prudencio et al., 2012), further sug-
gesting that dysfunction of TDP-43 underlies FTD pathogenesis.
Collectively, deregulation of TDP-43 RNA targets supports loss
of nuclear TDP-43 function as a plausible contributor to patho-genesis after an initiating stress leading to cytoplasmic TDP-43
accumulation.
Mechanism(s) of ALS-Linked FUS/TLS Mutants
FUS Loss of Function in Disease
Like TDP-43, loss of nuclear function of FUS/TLS is also a likely
component of the disease process, as nuclear clearing accom-
panied by cytoplasmic accumulation of FUS/TLS was initially
reported in surviving neurons of patients with NLS mutant-
mediated FUS/TLS (Kwiatkowski et al., 2009; Vance et al.,
2009). Two independent FUS/TLS knockout mouse models
have been generated (Kuroda et al., 2000; Hicks et al., 2000).
Conflicting results from these models have made it unclear
whether FUS/TLS is an essential gene.
FUS/TLS Mutant Gain of Toxicity
No currently published mouse model stably express ALS-linked
mutations in FUS/TLS. However, one study in rats with inducible
expression of human wild-type or R521C mutant of FUS/TLS
reported that postnatal induction (to undetermined levels) in
two independent lines of mutant-expressing rats produced
paralysis and death by 70 days of age, whereas comparable
wild-type human FUS/TLS-expressing rats survived normally
(Huang et al., 2011). These findings support a gain of toxicity
by mutant FUS/TLS, albeit rats overexpressing wild-type FUS/
TLS also develop motor and spatial learning deficits accompa-
nied by ubiquitin aggregation by 1 year of age. It should be noted
that, similar to the case of TDP-43, increased wild-type FUS/TLS
accumulation through homozygous mating in mice is also highly
deleterious, driving early lethality (Mitchell et al., 2013). Addi-
tional mouse and rat models and further studies are needed to
elucidate FUS/TLS-mediated toxicity.
Is TDP-43 and FUS/TLS-Mediated Toxicity a
Non-Cell-Autonomous Process?
An increasing body of evidence has established that cell
types beyond the target neurons whose dysfunction is respon-
sible for the primary phenotypes also contribute to neurode-
generation, a phenomenon known as non-cell-autonomous
toxicity (Garden and La Spada, 2012). Given that TDP-43
and FUS/TLS inclusion can also be found in glia (Mackenzie
et al., 2010a), it is conceivable that glia contribute to disease
pathogenesis. Indeed, induced pluripotent stem cell (iPSC)-
derived astrocytes from patients carrying a familial mutation
in TDP-43 (M337V) showed several abnormalities, including
increased TDP-43 accumulation and altered subcellular
localization (Serio et al., 2013). While these mutant astrocytes
did not produce short-term toxicity to cocultured motor
neurons, driving expression only in astrocytes of the same
TDP-43 mutation (M337V) produced progressive loss of motor
neurons and paralysis in rats (Tong et al., 2013). Thus, it is
highly plausible that TDP-43 (and possibly FUS/TLS as
well) mediated neurodegeneration is a non-cell-autonomous
process.
TDP-43, FUS/TLS, and a Potential Link between Stress
Granules and Protein Inclusion
TDP-43 and FUS/TLS are components of stress granules
(Dewey et al., 2012; Li et al., 2013). The main functions of stress
granules appear to be in temporally repressing generalNeuron 79, August 7, 2013 ª2013 Elsevier Inc. 421
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stress granules are disassembled when the stressors are
removed (Anderson and Kedersha, 2009).
At least seven independent studies have reported TDP-43 to
be localized within stress granules produced in a wide range of
cell lines with varying stresses, including oxidative, osmotic,
and heat stresses (Ayala et al., 2011a; Colombrita et al., 2009;
Dewey et al., 2011; Freibaum et al., 2010; Liu-Yesucevitz et al.,
2010; McDonald et al., 2011; Meyerowitz et al., 2011). TDP-43
variants with ALS-linked mutations appear to form larger stress
granules with faster kinetics (Dewey et al., 2011; Liu-Yesucevitz
et al., 2010) and this requires the prion-like domain (Bentmann
et al., 2012; Dewey et al., 2011; Liu-Yesucevitz et al., 2010).
Similarly, FUS/TLS is recruited into stress granules (Andersson
et al., 2008) and FUS/TLS with ALS-linked mutations in its NLS
show enhanced propensity to associate with stress granules
(Bosco et al., 2010a; Dormann et al., 2010; Gal et al., 2011; Ito
et al., 2011; Kino et al., 2011). One provocative report claimed
that the prion-like domain of FUS/TLS is both necessary and
sufficient to form stress granules in cultured cells and to form
hydrogels in vitro (Kato et al., 2012). Another report claimed
a completely opposite result, with the C-terminal residues
together with an ALS-linked mutation (P525L), but not the
prion-like domain, required for stress granule formation in cells
(Bentmann et al., 2012). The discrepancy remains unresolved.
Nonetheless, the evidence collectively indicates that associa-
tion of TDP-43 and FUS/TLS into stress granules is a normal
physiological response to stress. A tempting speculation is
that the association of TDP-43 and FUS/TLSwith stress granules
may be an initiating event, which following chronic stress even-
tually leads to irreversible pathological aggregation (Dormann
et al., 2010; Dewey et al., 2012; Li et al., 2013). However, caution
is warranted, as these cell culture experiments used overexpres-
sion of TDP-43 and FUS/TLS and do not recapitulate one key
feature of TDP-43 and FUS/TLS proteionopathies: concomitant
loss of nuclear TDP-43 or FUS/TLS with cytoplasmic inclusions
(Mackenzie et al., 2010a).
TDP-43 is transiently lost from neuronal nuclei with concomi-
tant accumulation at injury sites in two in vivo experiments in
mice using either axotomy or axonal ligation (Moisse et al.,
2009; Sato et al., 2009). Interestingly, mutant TDP-43 showed
a delayed response in returning to the nucleus during recovery
(Swarup et al., 2012). Since current evidence suggests that at
disease end stage TDP-43 and FUS/TLS associate with stress
granules in ALS and FTD patients (Dormann et al., 2010; Liu-
Yesucevitz et al., 2010), future investigation should now focus
on how TDP-43 and FUS/TLS switch from reversible association
into irreversible pathological inclusions, what the relationship is
between this process and the nuclear clearance of TDP-43 and
FUS/TLS, and how the combination of pathological inclusions
and loss of nuclear TDP-43 and FUS/TLS drives disease
progression.
TDP-43, FUS/TLS, and SMN, a Common Pathogenic
Pathway between ALS and Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a motor neuron disease
caused by deficiency in the survival motor neuron (SMN) protein
(reviewed in Burghes and Beattie, 2009). SMN is part of a large422 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.multiprotein complex that is essential for the biogenesis of spli-
ceosomal-associated small nuclear ribonucleoprotein particles
(snRNPs). SMN complexes are found both in the cytoplasm
and in nuclear bodies called Gems. Loss of nuclear Gems is a
pathological hallmark in SMA. Reduced SMN expression leads
to markedly decreased snRNP assembly and reduced snRNA
levels in mouse models of SMA and in SMA patients, provoking
broad misregulation of RNA splicing.
Recent evidence suggests that perturbation of normal levels
of TDP-43 (Shan et al., 2010; Tsuiji et al., 2013) or FUS/TLS
(Yamazaki et al., 2012) or expression of ALS-linked mutations
in TDP-43 (Yamazaki et al., 2012) and FUS/TLS (Groen et al.,
2013; Yamazaki et al., 2012) leads to reduction of nuclear GEM
bodies, altered U snRNA expression, and axonal defects, likely
through a direct biochemical association between SMN and
TDP-43 (Tsuiji et al., 2013) or FUS/TLS (Groen et al., 2013;
Yamazaki et al., 2012). Moreover, these SMN deficits are also
found in sporadic ALS patients with TDP-43 inclusions (Ishihara
et al., 2013; Tsuiji et al., 2013). Taken together, the collective
evidence supports convergent pathways of pathogenesis in
SMA and ALS, reinforcing the notion that defects in RNA meta-
bolismmay be central mechanistic components in motor neuron
disease.
Repeat Expansion within C9ORF72
Genome-wide association studies (GWASs) of familial ALS
patients in the Finish population, as well as in sporadic ALS,
demonstrated the presence of a major ALS locus on chromo-
some 9p21 (Laaksovirta et al., 2010; Shatunov et al., 2010; Van
Deerlin et al., 2010; van Es et al., 2009). The minimal region link-
ing all the families was then narrowed down to a 232 kb interval
containing only three protein-coding genes (MOBKL2B, IFNK,
and C9ORF72) (Laaksovirta et al., 2010). Rather than the ex-
pected amino acid substitutions in a protein coding region, a
large GGGGCC hexanucleotide repeat expansion (700–1,600
copies) within a noncoding region of a gene (C9ORF72) was
found to be causative (DeJesus-Hernandez et al., 2011;
Gijselinck et al., 2012; Renton et al., 2011).
Hexanucleotide expansion in C9ORF72 accounts for up to
80% of familial ALS-FTD, 20%–50% of familial ALS, 5%–20%
of sporadic ALS, and 10%–30% of FTD, making this repeat
expansion the most common cause of ALS and FTD (Boeve
et al., 2012; Chio` et al., 2012; Cooper-Knock et al., 2012; Hsiung
et al., 2012; Mahoney et al., 2012; Simo´n-Sa´nchez et al., 2012;
Snowden et al., 2012). Clinically, patients with the C9ORF72
repeat expansion have been reported to have a higher incidence
of bulbar-onset ALS, cognitive impairment with earlier disease
onset, and accelerated progression compared with patients
without the expansion (Byrne et al., 2012; Chio` et al., 2012;
Millecamps et al., 2012; Stewart et al., 2012).
Inclusions containing TDP-43 in brain and spinal cord are
prevalent in all patients with the repeat expansion. Additionally,
there is the presence of TDP-43-negative cytoplasmic or
nuclear inclusions containing either p62/SQSTM1 or ubiquilin-2
or both in the cerebellar granular and molecular layers (Brettsch-
neider et al., 2012). Similarly, TDP-43 pathology is absent
from neuronal intranuclear and cytoplasmic inclusions in the











































































Figure 4. Potential Pathogenic Mechanisms for GGGGCC Repeat Expansion within the C9ORF72 Gene
Top: schematic representation of the human C9ORF72 gene (yellow, UTRs; blue, coding exons). Hexanucleotide (GGGGCC) repeat expansion is located
between alternative exons 1a and 1b. At least three mechanisms may contribute to disease pathogenesis: (A) GGGGCC repeat expansions may lead to reduced
expression of the allele containing the repeat expansion (haploinsufficiency); (B) RNA foci containing transcribed GGGGCC repeats may sequester RNA-binding
protein(s); or (C) repeat associated non-AUG (RAN) translation of GGGGCC repeat-containing RNA produces toxic polydipeptides in each of three reading
frames. Data and images reproduced with permission from (A) Gijselinck et al. (2012), (B) DeJesus-Hernandez et al. (2011), and (C) Mori et al. (2013b).
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Troakes et al., 2012), suggesting that additional component(s)
other than TDP-43 are present in the inclusions. Cytoplasmic
ubiquilin-2-containing inclusions have also been reported in
the cerebellar granular and hippocampal molecular layers
(Brettschneider et al., 2012).
Pathogenic Mechanisms for the Repeat Expansion in
C9ORF72 Gene
The expanded hexanucleotide repeat in the C9ORF72 gene is
reminiscent ofmultiple prior repeat expansion diseases for which
three different prototypes of pathogenic mechanisms have been
demonstrated: loss of function of the gene containing the repeat
(haploinsufficiency), gain of protein toxicity due to the expression
of protein containing the repeat expansion (mutant protein), and
gain of RNA toxicity due to the production of RNA containing the
repeat (mutant RNA) (La Spada and Taylor, 2010). Additional
toxic mechanisms can result from complementary repeat-con-taining RNA produced by bidirectional transcription (Moseley
et al., 2006) or repeat associated non-ATG (RAN) translation
(Zu et al., 2011), leading to production, respectively, of potentially
toxic RNA and protein species. For C9ORF72, because the
GGGGCC repeat expansion is located within an alternative non-
coding intron 1, the underlying disease pathogenesis may be
driven by RNA-mediated or RAN translation-dependent toxicity
or haploinsufficiency or any combination of these (Figure 4).
Loss of Function and Gain of Toxicity: Lessons from the
Fragile X Locus and Myotonic Dystrophy
The location of the repeat expansion in intron 1 of C9ORF72
resembles the CGG repeats of the FMR1 (fragile X mental retar-
dation 1) gene, which, depending on the size of the repeats,
yields three different syndromes: fragile X syndrome (>200
repeats), fragile X-associated tremor/ataxia syndrome (50–200
repeats), and premature ovarian insufficiency (50–200 repeats)
(Oostra and Willemsen, 2009). Full expansion causes fragile XNeuron 79, August 7, 2013 ª2013 Elsevier Inc. 423
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hypermethylation of the adjacent FMR1 promoter region and
subsequent transcriptional silencing.
FMR1 carriers with CGG repeats between 50 and 200 develop
fragile X-associated tremor/ataxia syndrome (FXTAS) in which
the repeats are unmethylated but produce intention tremor,
abnormal gait, peripheral neuropathy, and cognitive impairment
(Oostra and Willemsen, 2009). In contrast to transcriptional
silencing in FXS (Tassone et al., 2000), accumulation of FMR1
mRNA in FXTAS is elevated at least 5-fold, presumably because
it is stabilized by binding of hnRNP A2/B1, Pur-a (purine-rich
binding protein-a), Sam68, hnRNP-G, along with CUG-binding
protein 1 (CUG-BP1) and muscleblind (MBNL1), each of which
has been shown either to associate biochemically with the
rCGG repeats or colocalize with rCGG RNA foci (Jin et al.,
2007; Sellier et al., 2010; Sofola et al., 2007). Furthermore, both
Sam68 and hnRNP A2/B1 can be found in the nuclear inclusions
of FXTAS patient neurons (Jin et al., 2007; Sellier et al., 2010).
While the identities of other RNA-binding proteins potentially
trapped in the rCGG foci and the underlying pathogenic
mechanisms remain controversial, it is clear that RNA-mediated
toxicity is a key component of neurodegeneration in FXTAS.
These complications should be borne in mind in considering
whether different repeat sizes within the C9ORF72 gene may
provide divergent symptoms/diseases or different severity of
phenotypes.
A gain-of-RNA-toxicity mechanism for a repeat expansion dis-
ease is best characterized in myotonic dystrophy 1 (DM1), which
is caused by up to 2,500 of CTG repeats in the 30UTR of themyo-
tonic dystrophy protein kinase (DMPK) gene (Lee and Cooper,
2009). Two proteins, CUG-BP1 and muscleblind, were identified
to bind to the CUG repeat-containing RNA (Miller et al., 2000;
Timchenko et al., 1996). Of these two proteins, only muscleblind
shows repeat-length-dependent association and is selectively
sequestered into pathogenic RNA foci (Mankodi et al., 2001).
Nevertheless, misregulation of both muscleblind and CUG-BP1
play roles in DM1 pathogenesis. Indeed, CUG repeats lead to
activation of protein kinase C (PKC), which in turn phosphory-
lates CUG-BP1, whose phosphorylated form has increased
activity from increased protein stability, thereby activating multi-
ple splicing changes toward fetal isoforms (Kuyumcu-Martinez
et al., 2007; Roberts et al., 1997).
Evidence for C9ORF72 Haploinsufficiency
The functionof theC9ORF72geneand itspredictedproteinprod-
uct are unknown. Recent bioinfomatical analysis implies a poten-
tial involvement of the C9ORF72 protein in membrane trafficking
and autophagy (Levine et al., 2013; Zhang et al., 2012), but this
remains to be determined. A 50% reduction of mRNA levels cor-
responding to both short and long mRNA isoforms of C9ORF72
(DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012) has
been reported and is consistentwith partial or complete silencing
of the expanded allele (Figure 4A), although it should be noted
that the reduction of the corresponding C9ORF72 proteins has
not been demonstrated. Antisense oligonucleotide-mediated
reduction of C9ORF72 in zebrafish produces reduced axon
lengths of motor neurons and locomotion deficit (Ciura et al.,
2013), consistent with the notion that partial loss of the
C9ORF72 gene could contribute to disease pathogenesis.424 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.Evidence for Gain of RNA Toxicity from C9ORF72
Expansion
Intranuclear RNA foci containing the C9ORF72 hexanucleotide
repeat have been reported (DeJesus-Hernandez et al., 2011),
which may trap one or more RNA-binding proteins, thereby in-
hibiting their functions, especially in RNA processing (Figure 4B).
While two RNA-binding proteins, hnRNP-A3 (Mori et al., 2013a)
and Pur-a (Xu et al., 2013), have been reported to bind GGGGCC
repeats in vitro and both were reported to be components of
p62-positive TDP-43-negative inclusions in C9ORF72 patients,
their role in pathogenesis is unproven. Neither has been demon-
strated to localize at RNA foci formed by the hexanucleotide
repeat and the predicted loss of RNA processing function that
would follow from sequestration of hnRNP-A3 and Pur-a has
not been demonstrated in cells and tissues expressing the hex-
anucleotide repeat-containing RNA.
Repeat Non-ATG Translation of C9ORF72 mRNA
Besides the recognizedmodes of RNA toxicity introduced above,
ahighlyunexpectedandpotentially toxicmechanism inC9ORF72
hasbeenuncovered: repeat-associatedRNA-encoded,non-ATG
translation (RAN translation). This phenomenon was originally
discovered in spinocerebellar ataxia type 8 (SCA8), a progres-
sive neurodegenerative disease causedby a trinucleotide expan-
sion in the bidirectionally transcribed SCA8 gene (Zu et al., 2011).
In one direction, the RNA encoding the ataxin 8 (ATXN8) protein
contains an in-frame CAG-expansion that is translated into
polyglutamine. Surprisingly, this RNA is also translated in an
ATG-independent manner in all three reading frames of the
CAG repeat both in vitro and in SCA8 human cerebellum.
Following the SCA8 example, two independent studies have
now reported translation of the C9ORF72 GGGGCC repeat
into polypeptides consisting of repeating di-amino acids:
poly-(glycine-alanine, GA), poly-(glycine-proline, GP), and poly-
(glycine-arginine, GR) (Figure 4C) that form pathological inclu-
sions in neurons (but not astrocytes) of C9ORF72 patients (Ash
et al., 2013; Mori et al., 2013b). Poly-GA is apparently the most
prevalent form (Mori et al., 2013b). Moreover, an antisense
RNA transcript in C9ORF72 patients has also been reported
(Mori et al., 2013b), raising the possibility of two additional dipep-
tide-repeats (poly-PR and poly-PA), which may also be gener-
ated through RAN translation.
More Complexities in Repeat-Mediated Toxicity
If the preceding potential toxicities were not enough, consider-
ation of what is known about SCA8 providesmore potential com-
plexities. As mentioned above, the SCA8 locus is bidirectionally
transcribedwith opposite strand transcription of the CAG repeat,
producing a noncoding RNA containing a CUG repeat expansion
that sequesters muscleblind, leading to splicing changes similar
to those observed in DM1 patients (Daughters et al., 2009;
Moseley et al., 2006). Added to potential RAN translation of
both CAG and CUG repeats, the pathogenic mechanisms
include gain of function at both the protein and RNA levels.
Disruption of Protein Homeostasis in ALS and FTD
Although the chicken-and-egg question persists for whether
protein aggregation per se causes or merely reflects a conse-
quence of neurodegenerative diseases, overwhelming evidence























































































Figure 5. ALS/FTD-Associated Proteins Involved in Protein Homeostasis
(A–C) Schematic representation of major cellular degradation pathways. (A) Many ALS/FTD-linked proteins are involved in protein clearance pathway, including
(B) ubiquilin-2 (UBQLN2) and p62/SQSTM1 (which bind to polyubiquitinated proteins and transport them to proteasome for degradation) and (C) p62/SQSTM1
and optineurin (OPTN) (which serve as adaptor proteins to bind simultaneously the substrates that are targeted for autophagy and LC3, a component of
autophagosomes).
(D) FIG4 is a lipid phosphatase that converts PI(3,5)P into PI3P. Autophagy is impaired in the neurons and astrocytes missing FIG4, with the disturbance of PIPs
expected to disrupt formation or recycling of autolysosomes.
(E) ALS/FTD-linked mutations in CHMP2B, a core component of endosomal sorting complexes (ESCRT) required for transport, disrupt the normal endosome-
lysosome-autophagy morphology and function. ESCRT complexes bind to ubiquitinated cargos and initiate clustering of ubiquitinated cargos and membrane
invagination. The internalized cargos, which are cell membrane proteins, are transported into autophagosomes for degradation.
(F) VCP interacts with a large number of cofactor proteins that act as ubiquitin adaptors, allowing VCP to interact with a large number of ubiquitinated proteins to
enable degradation or recycling, including extraction of misfolded proteins from the ER and subsequently targeting them for degradation.
(G) VAPB is involved in the unfolded protein response (UPR) by modulating activities of the IRE1 and ATF6 arms of the UPR.
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clearance pathways: the ubiquitin-proteasome system and
autophagy. This is certainly true for ALS/FTD, as demonstrated
by identification of ALS- and FTD-linked mutations in genes
affecting protein homeostasis, or proteostasis. These genes
include ubiquilin-2 (UBQLN2), p62/SQSTM1 (sequestosome 1),
optineurin (OPTN), vasolin-containing protein (VCP), charged
multivesicular body protein 2B (CHMP2B), vesicle-associated
membrane protein (VAMP)/synatobrevin-associated protein B
(VAPB), and FIG4 (FIG4 homolog, SAC1 lipid phosphatase
domain containing protein) (Figure S2). Among these genes,
ubiquilin-2, p62, optineurin, and VCP are directly involved in pro-
tein degradation, whereas CHMP2B and FIG4 are required for
autophagosome maturation (Figure 5).
ALS-FTD mutation in Ubiquilin-2
The ubiquilin protein family brings polyubiquitinated proteins
to the proteasome for degradation, and ubiquilins also functionin autophagy. The ALS and ALS/dementia-linked mutations
initially identified in UBQLN2 are clustered at or near its
proline-rich region, with most altering a conserved proline
(P497H, P497S, P506T, P509S, P525S) (Deng et al., 2011;
Gellera et al., 2013; Williams et al., 2012). Two additional muta-
tions, S155N and P189T, are located at the N terminus (Daoud
et al., 2012). Experiments in cells transfected to express either
of two ALS-linked mutations in ubiquilin-2 (R497H and P506T)
suggest that that overall protein degradation is impaired (Deng
et al., 2011).
Perhaps not surprisingly, colocalization of ubiquilin-2 and
ubiquitin in pathological inclusions is seen in patients with
UBQLN2 mutations and these inclusions also contain TDP-43,
FUS/TLS, and optineurin (Deng et al., 2011; Williams et al.,
2012), suggesting that an impaired protein clearance pathway
is a pathogenic mechanism (Figure 5B). Furthermore, ubquilin-2
pathology has been reported in a majority of sporadic ALS
(Deng et al., 2011) and hexanucleotide repeat expansion in theNeuron 79, August 7, 2013 ª2013 Elsevier Inc. 425
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mutations in ubiquilin-2 provide a mechanistic link of the protein
degradation pathway with neurodegeneration.
p62/SQSTM1 Mutations in ALS
Similar to ubiquilin, p62 has been shown to interact with polyubi-
quitinated proteins (Moscat and Diaz-Meco, 2012) and to
interact with LC3, allowing p62 to target polyubiquitinated pro-
teins to the proteasome or autophagy. Therefore, both p62 and
ubiquilin-2 link the ubiquitin-proteasome and autophagy path-
ways (Figures 5B and 5C). Using a candidate gene approach,
sequencing of p62/SQSTM1 in familial and sporadic ALS
patients revealed several polymorphisms/mutations scattered
throughout the coding regions (Fecto et al., 2011; Rubino
et al., 2012; Teyssou et al., 2013), accompanied by TDP-43 inclu-
sions (Teyssou et al., 2013). p62-positive inclusions have also
been reported in neurons and glia of a wide array of other neuro-
degenerative diseases (Brettschneider et al., 2012). Although
how these ALS-associated variants in p62 contribute to patho-
genesis has not been established, autophagy/proteasome
disturbance seems likely to play a role.
ALS Mutations in Optineurin
Optineurin (OPTN) is a 577 amino acid multifunctional protein
that is able to bind both polyubiquitinated proteins and LC3
(Figure 5C). Indeed, optineurin has been proposed as a receptor
for autophagy (Wild et al., 2011). Both nonsense and missense
mutations of optineurin have been identified in ALS, accounting
3% of familial ALS and 1% of sporadic ALS (Del Bo et al.,
2011; Iida et al., 2012a, 2012b; Maruyama et al., 2010; van
Blitterswijk et al., 2012). One report has identified OPTN-positive
inclusions in patients with OPTN mutation, with TDP-43 inclu-
sions in sporadic ALS and with SOD1-positive inclusions in
patients with SOD1 mutations (Maruyama et al., 2010).
ALS- and FTD-Linked Mutations in Vasolin-Containing
Protein
Mutations in vasolin-containing protein (VCP) were originally
identified as causative of inclusion body myopathy with Paget’s
disease of bone and frontotemporal dementia (IBMFTD)
(Watts et al., 2004) and later in ALS (Johnson et al., 2010).
Some of the same mutations have been found for both IBMFTD
and ALS (Figure S2). VCP interacts with a large number of ubiq-
uitinated proteins to enable degradation or recycling and func-
tions in multiple protein clearance pathways (Figure 5F),
including extracting misfolded proteins from the ER and sorting
of endosomal proteins for proper trafficking. Depletion of VCP
leads to accumulation of immature autophagosomes, similar to
what is observed upon expression of IBMFD-linked mutations
(Ju et al., 2009; Tresse et al., 2010), suggesting that VCP is
required for proper autophagy. Most intriguingly, TDP-43 is
apparently mislocalized to the cytosol upon VCP-mediated auto-
phagic dysfunction (Ju et al., 2009).
FTD- and ALS-Linked Mutations in CHMP2B
Charged multivesicular body protein 2B, or chromatin-modifying
protein 2B (CHMP2B) mutations were first identified in FTD
(termed FTD-3) (Momeni et al., 2006; van der Zee et al., 2008)
and later in ALS (Cox et al., 2010; Parkinson et al., 2006).
CHMP2B is a core component of endosomal sorting complexes
(reviewed in Raiborg and Stenmark, 2009) (Figure 5E). Multiple
studies support mutant CHMP2B-mediated disruption normal426 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.endosome-lysosome-autophagy morphology and function
(Han et al., 2012a; Urwin et al., 2010; van der Zee et al., 2008).
Transgenic mice expressing the intron 5-retention mutant of
CHMP2B, but not wild-type CHMP2B, develop progressive
neurological deterioration accompanied by axonal pathology
and early mortality (Ghazi-Noori et al., 2012). Loss of CHMP2B
function, on the other hand, after gene disruption in mice pro-
duces no phenotype (Ghazi-Noori et al., 2012).
ALS Mutations in FIG4
FIG4 encodes a 907 amino acid lipid phosphatase that regu-
lates the abundance of phosphatidyl-inositol-3,5-biphosphate
(PI(3,5)P2). Recessive mutation in FIG4 causes severe tremor,
abnormal gait, degeneration of sensory and motor neurons,
and diluted pigmentation in mice. Compound heterozygote
mutations, in which a loss-of-function allele combineswith a par-
tial loss-of-function mutation, are present in human patients with
Charcot-Marie-Tooth disease (CMT4J) (Chow et al., 2007), as
are rare, heterozygous variants of FIG4 in ALS (Chow et al.,
2009). FIG4 null mice have substantially lowered PI(3,5)P2 levels,
which are normally tightly regulated. Not surprisingly, autophagy
is impaired in the neurons and astrocytes of mice missing FIG4,
with the disturbance of PIPs expected to disrupt formation or
recycling of autolysosomes. It is tempting to speculate that
ALS-linked variants can tip the balance of phosphoinositide pro-
cessing and affect autophagic function (Figure 5D).
ALS Mutations in VAPB
Two ALS-linked mutations in the gene encoding VAMP/VAPB
have been reported (Figure S2) (Chen et al., 2010; Funke et al.,
2010; Millecamps et al., 2010; Nishimura et al., 2004). Expres-
sion of either, but not wild-type, in mammalian cell lines pro-
duced ER fragmentation and cytoplasmic aggregates of mutant
VAPB that also trapped endogenous VAPB (Chen et al., 2010;
Kanekura et al., 2006; Nishimura et al., 2004; Teuling et al.,
2007). Increased levels of wild-type VAPB elicit the unfolded pro-
tein response (UPR) (Figure 5G). Reduction in VAPB attenuates
the UPR, as do ALS-linked mutants (Chen et al., 2010; Kanekura
et al., 2006), probably by interaction with ATF6, one of the three
key molecules in initiating the UPR response (Gkogkas et al.,
2008). Transgenic mice expressing wild-type or mutant VAPB
(P56S) within the nervous system do not, however, develop overt
phenotypes or have reduced survival but do develop cyto-
plasmic accumulation of ubiquitin, p62, and TDP-43 at
18 months of age (Qiu et al., 2013; Tudor et al., 2010). Neverthe-
less, along with ALS-, FTD-, and ALS/FTD-linked mutations in
ubiquilin-2, p62, optineuron, VCP, CHMP2B, and FIG, the
VAPB mutations point to defects in protein clearance as a com-
mon component of pathogenesis.
A surprising additional function of VAPB came from study in
Drosophila of its MSP (major sperm protein) domain (Tsuda
et al., 2008). The MSP domain has been reported to be cleaved
and secreted, while the ALS-linked P56S mutant abolished the
secretion activity and formed ubiquitinated inclusions. Patho-
genicmechanismsmay involveaberrant Ephsignaling.Biochem-
ically, human MSP interacts with EphA4 (Tsuda et al., 2008), a
receptor in the ephrin axonal repellent pathway. Intriguingly,
EphA4 has been reported to be a genetic modifier for modulating
the vulnerability of motor neurons in ALS (Van Hoecke et al.,
2012). How the MSP-like fragment is generated in a
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role in modulating ALS disease course will require further investi-
gation.
SOD1: A Central Component of ALS or an Outlier?
Mutations in the copper/zinc superoxide dismutase 1 (SOD1)
gene account for 20% of familial ALS cases (Rosen et al.,
1993). Mouse models overexpressing ALS-linked mutations in
SOD1 recapitulate most features of ALS pathology, which has
led to the discovery of two critical features of SOD1-mediated
toxicity: (1) mutant SOD1 causes ALS through a gain of toxic
property (or properties), and (2) pathogenesis of the ubiquitously
expressed mutant SOD1 is a non-cell-autonomous process.
This latter insight was established by gene excision from
selected cell types in transgenic mice otherwise expressing
mutant SOD1 ubiquitously, an approach that identified disease
onset to be driven by mutant synthesized within motor neurons
(Boille´e et al., 2006; Wang et al., 2009; Yamanaka et al., 2008)
and NG2+ oligodendrocyte precursors (Kang et al., 2013), while
mutant SOD1 synthesized within two additional glial cell types
(astrocytes; Yamanaka et al., 2008; and microglia; Boille´e
et al., 2006) are primary determinants of accelerated disease
progression.
A Crucial Controversy: Is SOD1 a Component of
Sporadic Disease?
While ubiquitinated protein aggregates containing SOD1 are a
prominent pathological feature in both familial ALS patients
with SOD1 mutations and in mice expressing ALS-linked muta-
tions in SOD1 (Bruijn et al., 2004), SOD1-containing inclusions
have not been found in most sporadic ALS cases. Nevertheless,
early studies hinted that an age-dependent posttranslational and
nonmutational modification of SOD1 may be able to change the
conformation of wild-type SOD1 into an altered conformation
(Bredesen et al., 1997), suggesting that these modified forms
of wild-type SOD1 could be contributors to sporadic ALS. The
notion that there is a common pathogenic conformation of
wild-type and mutant SOD1 has recently made a comeback.
Several teams have reported that misfolded SOD1 is present in
a portion of sporadic ALS patients (Bosco et al., 2010b; Forsberg
et al., 2010; Pokrishevsky et al., 2012). This issue remains highly
controversial, with other teams failing to detect misfolded SOD1
in sporadic ALS patients using multiple conformation-specific
antibodies (Brotherton et al., 2012; Kerman et al., 2010; Liu
et al., 2009).
SOD1 mutant-expressing astrocytes are toxic to cocultured
normal motor neurons (Di Giorgio et al., 2007, 2008; Haidet-
Phillips et al., 2011; Marchetto et al., 2008; Nagai et al., 2007).
Kaspar and colleagues (Haidet-Phillips et al., 2011) reported
the very surprising finding that astrocytes derived from autopsy
samples from sporadic ALS patients are also toxic to motor neu-
rons. Most provocatively, this team also reported that non-cell-
autonomous toxicity to motor neurons from such sporadic
ALS-derived astrocytes can be reduced by lowering production
of wild-type SOD1, thereby implicating wild-type SOD1 as a
contributing factor in sporadic disease. While replication is
needed, these results highlight non-cell-autonomous compo-
nents in ALS pathogenesis and support therapeutic reduction
of SOD1 expression in sporadic ALS.Prion-like Spreading for ALS and FTLD
One of the key features of prion diseases is the conformational
conversion of a native state to an infectious, misfolded, and
pathological state of the prion protein. The infectious cycle
comes from the perpetuating conversion of the normal prion pro-
tein into a pathological conformation and spreading to other
cells, a process that has now been demonstrated for neurode-
generative diseases such as Alzheimer’s and Parkinson’s dis-
ease (reviewed in Polymenidou and Cleveland, 2012).
Consistent with a prion-like spread, ALS-linked mutant SOD1
can form fibrils (Chattopadhyay et al., 2008) and mutant SOD1
has been shown to possess prion-like aggregation and
spreading ability in cultured cells (Grad et al., 2011; Mu¨nch
et al., 2011), as well as seeding ability using spinal cord homog-
enate from transgenic animals overexpressing mutant SOD1
(Chia et al., 2010) (Figure 6). Remarkably, increased wild-type
SOD1 expression (accompanied by its conversion into an insol-
uble form) is sufficient to accelerate disease course and shorten
survival of SOD1 mutant-expressing mice (Deng et al., 2006),
consistent with a prion-like template-dependent aggregation.
Furthermore, both TDP-43 and FUS/TLS contain prion-like
domains, which may facilitate seeding and aggregation
(Figure 6). Indeed, a recent study reported that intracellular
aggregation of TDP-43 can be triggered in cultured cells by
transduction of fibrillar aggregates prepared in vitro (Furukawa
et al., 2011). More provocatively, insoluble TDP-43 isolated
from brains of ALS or FTLD-TDP patients can trigger prion-like
templating and aggregation of transfected TDP-43 in cultured
cells (Nonaka et al., 2013). In addition, disease-linked mutations
in prion-like domains in hnRNP-A2B1 and hnRNP-A1 increase
their propensity to form self-seeding fibrils and cross-assemble
with wild-type counterparts (Kim et al., 2013). Altogether, along
with recognition that the initial symptoms of ALS are typically
confined to a particular region, followed by an orderly spread
that might be predicted for prion-like propagation, the evidence
suggests that a prion-like seeding and spreading mechanism
could underlie TDP-43 and FUS/TLS-mediated disease.
Feedforward Loops: Converging Disruptions in RNA and
Protein Homeostasis
One of themost devastating features of ALS is the relentless pro-
gression and spread of degeneration. We attempt here to pro-
vide a molecular basis for this phenomenon. The recent discov-
ery of how RNA granules can form through a low-complexity/
prion-like domain in TDP-43, FUS/TLS, and hnRNP A2/B1 (Han
et al., 2012b; Kato et al., 2012) has fueled an attractive hypothe-
sis in which prion-like spreading of aggregated SOD1, TDP-43,
or FUS/TLS could contribute to ALS pathogenesis (Polymenidou
and Cleveland, 2011).
ALS-Linked Mutations in Protein Clearance Pathways
Can Lead to TDP-43 Aggregation
Both TDP-43 and FUS/TLS are intrinsically aggregation prone
in vitro (Johnson et al., 2009; Sun et al., 2011), whichmay predis-
pose them to formation of pathological inclusions through their
prion-like domains (Kato et al., 2012; Han et al., 2012b; Kim
et al., 2013), independent of any proposed progression from
an initiating stress granule complex (Dewey et al., 2012). Not sur-







Figure 6. Aggregate Assembly and Propagation in ALS and FTD
Prion-like phenomena in ALS may include SOD1-, TDP-43-, or FUS/TLS-seeded aggregation and cell-to-cell spreading.
(A) TDP-43 and FUS/TLS are both primarily nuclear RNA-binding proteins, whose mutations lead to ALS or FTD. Filled blue boxes on TDP-43 and FUS/TLS
molecules indicate RNA-recognition motifs and the striped blue box on FUS/TLS refers to the zinc finger domain that can also bind RNA.
(B) Cellular stress induces TDP-43 and FUS/TLS incorporation into stress granules, which form through the ordered aggregation of several RNA-binding proteins
complexed with RNA molecules. This physiologic reaction to cellular stress may be an initial trigger for pathogenic inclusion formation since the increased local
protein concentration and RNA scaffolding molecules may facilitate ordered aggregation of TDP-43 and/or FUS/TLS.
(C) Upon chronic cellular stress, defects in stress granule disassembly occurring with aging drive prion-like conformational changes of TDP-43 and FUS/TLS—
facilitated by disease-causing mutations in them and stress granule formation—transform into pathogenic self-perpetuating, irreversible aggregates.
(D) Possible cell-to-cell spread (not yet tested for TDP-43 or FUS/TLS) of prion-like aggregates may underlie (or at least contribute to) disease spread from a focal
initiation.
(E) Self-perpetuating seeding of misfolded, mutant SOD1 has been reported in cell cultures (Grad et al., 2011; Mu¨nch et al., 2011). Acquired damage to wild-type
SOD1 may seed similar self-perpetuating aggregates.
(F) Mutant, misfolded SOD1 can inducemisfolding of wild-type SOD1 in a template-directed reaction (Chia et al., 2010; Deng et al., 2006), thereby forming a seed
of aggregated protein.
(G) SOD1 aggregates transfer from cell to cell to initiate misfolding and aggregation of wild-type or mutant SOD1 in neighboring cells (Mu¨nch et al., 2011).
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et al., 2010; Wang et al., 2010). Mutations or disruption of
many of ALS-linked genes involved in protein homeostasis path-
ways (VCP, ubiquilin-2, p62, and CHMP2B) lead to TDP-43
aggregation.
Downregulation of VCP or expression of disease-linked muta-
tions of VCP generate cytosolic TDP-43 aggregations (Gitcho
et al., 2009; Ju et al., 2009; Ritson et al., 2010), autophagy
defects (Ju et al., 2009), and decreased proteasomal activity
(Gitcho et al., 2009). Similarly, reduction of CHMP2B and
expression of FTD-linked mutations in CHMP2B inhibit the
maturation of autolysosomes, which in turn lead to accumula-
tion of cytosolic TDP-43 aggregates (Filimonenko et al.,428 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.2007). Patients with ALS-FTD-linked mutations in ubiliqulin-2,
which appear to inhibit proteasome activity, develop TDP-43
proteinopathy (Deng et al., 2011). Ubiquilin-1 interacts with
TDP-43 and overexpression of ubiquilin-1 can recruit TDP-
43 into cytoplasmic aggregates that colocalize with autopha-
gosomes in cultured cells (Kim et al., 2009). Finally, p62/
sequestosome-1 is misaccumulated in both ALS and FTD
(Seelaar et al., 2007) along with TDP-43 (Tanji et al., 2012), while
increased expression of it reduces TDP-43 aggregates in
cultured cells (Brady et al., 2011). Taken together, these find-
ings indicate that ALS/FTD-linked mutations in genes that are
involved in protein homeostasis can directly contribute to
TDP-43 proteinopathy.
Neuron
ReviewExcept for ubquilin-2 mutations (Deng et al., 2011; Williams
et al., 2012), inclusion of FUS/TLS has not been reported in
response to mutations or disruption of ALS-linked genes
involved in the protein homeostasis pathways. However, as
described above, one class of ALS-linked mutations disrupts
nuclear localization signals, producing higher cytosolic accumu-
lation of FUS/TLS (Dormann et al., 2010; Bosco et al., 2010a).
This relocalization of FUS/TLS may be a primary cause for initi-
ating FUS/TLS proteinopathies.
TDP-43 Regulates Expression of ALS-Linked Genes
Involved in Protein Clearance
TDP-43 affects levels of RNAs that encode proteins involved in
protein homeostasis, including CHMP2B, FIG4, OPTN, VAPB,
and VCP (Polymenidou et al., 2011). Additionally, TDP-43 has
been shown to bind the pre-mRNA encoding the autophagy-
related 7 (Atg7) protein essential for autophagy, with reduction
of TDP-43 downregulating Atg7, thereby impairing autophagy
(Bose et al., 2011). It is worth mentioning that mice lacking
Atg5 and Atg7 in the nervous system exhibit neurodegeneration
(Hara et al., 2006; Komatsu et al., 2006), strongly suggesting—
not unexpectedly—that autophagy is essential for normal
neuronal function. Altogether, these results suggest an intricate
regulatory network in which TDP-43 can affect the expression
of the very gene(s) that participate in TDP-43 clearance,
providing an additional mechanism of regulating TDP-43 abun-
dance (the other being the autoregulation of TDP-43 by binding
to its own mRNA), while TDP-43 also indirectly affects global
protein clearance pathways by regulating the expression of
key components in autophagy.
Similarly, FUS/TLS binds to the mRNAs encoding optineurin
(Lagier-Tourenne et al., 2012; Colombrita et al., 2012),
ubiquilin-2 (Lagier-Tourenne et al., 2012; Hoell et al., 2011),
VAPB (Lagier-Tourenne et al., 2012; Hoell et al., 2011), and
VCP (Lagier-Tourenne et al., 2012; Colombrita et al., 2012; Hoell
et al., 2011), although reduction of FUS/TLS in the mouse CNS
does not significantly alter their expression levels (Lagier-
Tourenne et al., 2012). In a motoneuron-like cell line, FUS/TLS
has been argued to be preferentially bound to cytoplasmic
mRNAs that are involved in the ubiquitin-proteasome pathway,
in particular the cullin-RING E3 ubiquitin ligases (Colombrita
et al., 2012). Perhaps most importantly, the endoplasmic reticu-
lum or ubiquitin-proteasome pathways are overrepresented in
the mRNA targets bound by ALS-linked mutations in FUS/TLS
(Hoell et al., 2011). Altogether, the evidence strongly suggests
that, similar to the case for TDP-43, mutation or nuclear loss of
function of FUS/TLS affects protein clearance pathways by regu-
lating expression levels of genes in the pathway.
Unifying Underlying Pathogenic Pathways in ALS
and FTD
We propose that converging pathogenic mechanisms underly-
ing ALS and FTD are disruption of both RNA and protein
homeostasis and disturbed homeostasis that produces a feed-
forward loop that drives disease progression (Figure 7). In this
model, the initiating event that triggers disease initiation can
occur at multiple points in either protein or RNA homeostasis
pathways, including genetic mutations that predispose one
pathway to be more error prone or other nongeneticfactors, such as aging, in which proteostasis decline is well
documented.
More provocatively, prion-domain-containing RNA-binding
proteins may also be predisposed to self-promoting aggregation
and spread, which could explain the seemingly sporadic
nature of many instances of both diseases. Subsequent disease
progression may be amplified by failure in cross-regulation
among multiple proteins/genes, with several ALS-linked genes
(including VCP, p62/SQSTM1, and CHMP2B) required for TDP-
43 degradation, whereas TDP-43 regulates expression of VCP
and CHMP2B. In addition, not only does TDP-43 bind to its
own mRNA, which is essential for its autoregulation, but TDP-
43 also binds to several ALS-linked genes involved in RNA
homeostasis, including Ang1 (angiogenin), Atxn2 (ataxin-2),
and FUS/TLS. Similar mechanisms could exist for FUS/TLS.
Once initiated, errors in RNA and protein homeostasis accu-
mulate, which eventually lead to failure in autoregulation, dereg-
ulation of ALS-linked genes, proteotoxic stress, and loss of
neuroprotection. The failure to maintain proper protein and
RNA homeostasis is highly likely to drive a feedforward cycle,
leading to a snowballing effect perturbating many aspects
of protein and RNA function. Subsequent propagation and
spreading of TDP-43 and FUS/TLS aggregates into neighboring
cells could drive spread from a focal initiation site.
Prospects for Therapies in ALS/FTD
Following Jean-Martin Charcot’s initial description of ALS, he
made the grim statement regarding therapy, ‘‘The prognosis,
up to the present, is of the gloomiest. There does not exist, so
far as I am aware, a single example of a case where, the group
of symptoms just described having existed, recovery followed.’’
Sadly, 140 years has passed and ALS remains the same devas-
tating and lethal disease. There is currently only one FDA-
approved drug, riluzole, an inhibitor of presynaptic glutamate
release, which only extends the survival of the patients for
2–3months. In the past two decades, many potential therapeutic
interventions have been attempted but none have been success-
ful (reviewed in Zinman and Cudkowicz, 2011).
Therapies by Lowering Synthesis of a Toxic Species
For disease from mutant SOD1 (and if wild-type SOD1 is
confirmed to be a contributor to sporadic disease), therapy
lowering the synthesis of either would be directly on disease
mechanism. Indeed, reducing SOD1 expression has been re-
ported to slow disease progression of transgenic mice and rats
expressing human mutant SOD1 (Ralph et al., 2005; Raoul
et al., 2005; Smith et al., 2006). A further glimmer of hope has
emerged from a successful phase I safety trial using antisense
oligonucleotides against SOD1 in patients carrying mutant
SOD1 (Miller et al., 2013). A similar strategy targeting the poten-
tially toxic RNA species or RAN translation of it can be envisioned
for the more frequent instances of disease from hexanucleotide
expansion in C9ORF72.
Therapy Design by Improving Protein Homeostasis
Several lines of evidence indicate that broad defects in protein
homeostasis may contribute to ALS pathogenesis: (1) all ALS
patients have one of the following protein inclusions in affected
motor neurons: TDP-43, FUS/TLS, or SOD1; (2) ALS-linked
































































































Figure 7. Molecular Interplay of TDP-43
with Other ALS- and FTD-Linked Genes in
Protein and RNA Homeostasis
Proposed pathogenic mechanisms in TDP-43-
mediated neurodegeneration converge onto dis-
ruption of protein and RNA homeostasis. Proteins
involved in protein and RNA homeostasis are
labeled as gray and green, respectively. Top:
normal functions of ALS/FTD-linked proteins. (1)
Three ALS-linked genes (VCP, p62, and CHMP2B)
are required for proper turnover of TDP-43, which
is degraded both by the proteasome and by
autophagy. (2) TDP-43 regulates the expression of
the same ALS-linked genes that are required for its
own degradation as well as (3) a key autophagy
induction protein, ATG7. TDP-43 also regulates
two other RNA-binding proteins linked to ALS
(FUS/TLS and Ataxin-2). TDP-43, FUS/TLS, and
Ataxin-2 form RNA protein granules that are
degraded through (4) autophagy/granulophagy.
Thus, TDP-43 governs both protein and RNA
homeostasis and (5) its own level is tightly main-
tained. Bottom: disrupted protein and RNA
homeostasis that fuels a feedforward loop driving
disease progression. An initiating event that trig-
gers disease initiation can occur at multiple points
in either protein or RNA homeostasis pathways,
including genetic mutations that predispose one
pathway to be more error prone or other nonge-
netic factors, such as aging. The well-documented
(1) decline in proteostasis during aging may lead
to elevated accumulation of TDP-43. Subse-
quently, (2) the genes that are controlled by TDP-
43 become deregulated, including (3) loss of
expression of ATG7, which in turn reduces (4)
autophagy (and granulophagy). The net result of
this produces (5) disrupted autoregulation of TDP-
43 with an increased cytoplasmic concentration of
TDP-43, which provokes (6) prion-like templating
of it, followed by propagation and spread. These
gain-of-toxic properties induce overproduction of
‘‘nonfunctional prion-like’’ TDP-43 that leads to
further loss of TDP-43 function. Similar scenarios
could operate for prion-like domain-containing
RNA-binding proteins, such as FUS/TLS and
hnRNP A2/B1.
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linked mutations in ubiquilin-2, CHMP2B, and VCP can lead to
TDP-43 aggregation; (4) dysfunctions in ERAD and autophagy
are observed in mouse models expressing mutant SOD1; and
(5) autophagy appears to be activated and upregulated in motor
neurons of sporadic ALS patients.
It is not clear how a decline in general protein degradation
machinery might cause aggregation of specific proteins in
different neurodegenerative diseases. However, it is conceiv-
able that increasing (or delaying age-dependent decline in)
proteostasis could, in principle, prevent or slow down the for-
mation of protein inclusions—or at least accumulation of some
or all of the toxic protein species. Initial hints that this
approach could be beneficial came from report of modest
delay in disease progression following treatment of a very
small number of mice with arimoclomol, an inducer of heat
shock proteins HSP70 and HSP90 (Kieran et al., 2004). Phase
2/3 clinical trials are currently underway for this approach.430 Neuron 79, August 7, 2013 ª2013 Elsevier Inc.Dampening the UPR by deleting a downstream X-box-binding
protein (XBP-1) was reported to provide a modest survival
benefit (20 days) to a small cohort (n = 7) of SOD1G86R
mice, but the apparent benefit was disappointingly found
only in female mice (Hetz et al., 2009). Finally, pharmacological
activation of autophagy was reported in another small cohort
of mice (n = 10 per drug treatment) to improve cognitive and
motor phenotype in male mice overexpressing wild-type
TDP-43 (Wang et al., 2012).
Independent replications of the above experiments with larger
cohorts that are powered to provide statistical significance—and
extended to multiple ALS/FTD mouse models—are now needed
to validate the therapeutic potential of these approaches. More-
over, enthusiasm for the rationale of autophagy induction must
be tempered by recognition that simply activating the autophagy
pathway may cause cytosolic depletion of essential organelles
(reviewed in Wong and Cuervo, 2010), and it should be recog-
nized that autophagy is a double-edged sword.
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ReviewConcluding Remarks
With recent advances in identifying major common genetic
causes and the identities of major components in the patholog-
ical aggregates for ALS and FTD, perturbation of both RNA and
protein homeostasis is a convergent molecular feature with a
probable feedforward loop driving the failure in maintaining
RNA and protein homeostasis as a central underlying mecha-
nism for the relentless deterioration of neurons. There is probably
no silver bullet for curing all sporadic cases. However, with
knowledge of genetic causes and molecular players, it is the
most exciting time for discovery in ALS and FTD. Much remains
still to be learned, bearing in mind Charcot’s charge from 140
years ago, ‘‘Let us keep searching. It is indeed the best method
of finding and perhaps thanks to our efforts, the verdict we will
give such a patient (with ALS) tomorrow will not be the same
we must give this man today.’’
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